UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Emergence of the CD226 Axis in Cancer Immunotherapy

Frontiers in immunology, 2022-06, Vol.13, p.914406

2022

Volltextzugriff (PDF)

Distinct HP1 and Su(var)3-9 complexes bind to sets of developmentally coexpressed genes depending on chromosomal location

Genes & development, 2003-11, Vol.17 (22), p.2825-2838

2003

Volltextzugriff (PDF)

662 Dissecting the CD226 immune axis in the tumor microenvironment using CyTOF-based high-dimensional immunophenotyping

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A690-A690

2021

Volltextzugriff (PDF)

Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinations

Journal for immunotherapy of cancer, 2024-07, Vol.12 (7), p.e008677

2024

Volltextzugriff (PDF)

Big opportunities for small molecules in immuno-oncology

Nature reviews. Drug discovery, 2015-09, Vol.14 (9), p.603-622

2015

Volltextzugriff (PDF)

The Hinge and Chromo Shadow Domain Impart Distinct Targeting of HP1-Like Proteins

Molecular and Cellular Biology, 2001-04, Vol.21 (7), p.2555-2569

2001

Volltextzugriff (PDF)

Affinity Selection from Biological Libraries

Science (American Association for the Advancement of Science), 2002-10, Vol.298 (5593), p.621-622

2002

Volltextzugriff (PDF)

The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4

Clinical cancer research, 2015-04, Vol.21 (7), p.1639-1651

2015

Volltextzugriff (PDF)

Parental Expression of the Chromodomain Protein Pdd1p Is Required for Completion of Programmed DNA Elimination and Nuclear Differentiation

Molecular cell, 1999-11, Vol.4 (5), p.865-872

1999

Volltextzugriff (PDF)

Pdd1p, A Novel Chromodomain-Containing Protein, Links Heterochromatin Assembly and DNA Elimination in Tetrahymena

Cell, 1996-10, Vol.87 (1), p.75-84

1996

Volltextzugriff (PDF)

Immunological profiling of tumor-infiltrating CD8+ T lymphocytes in non-small cell lung cancer, head and neck squamous cell carcinoma, breast cancer, and renal cell cancer

The Journal of immunology (1950), 2022-05, Vol.208 (1_Supplement), p.179-179.10

2022

Volltextzugriff (PDF)

Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo

Molecular cancer therapeutics, 2021-10, Vol.20 (10), p.1941-1955

2021

Volltextzugriff (PDF)

Response to anti-PD-1 and anti-LAG-3 immune checkpoint blockade is associated with induction of pro-inflammatory Tregs

The Journal of immunology (1950), 2022-05, Vol.208 (1_Supplement), p.119-119.12

2022

Volltextzugriff (PDF)

Multimodal single-cell analysis of human TILs across multiple tumor types reveals heterogeneity and potential opportunities for personalized immunotherapy

The Journal of immunology (1950), 2022-05, Vol.208 (1_Supplement), p.179-179.14

2022

Volltextzugriff (PDF)

Molecular evidence that the myxozoan protists are metazoans

Science (American Association for the Advancement of Science), 1994-09, Vol.265 (5179), p.1719-1721

1994

Volltextzugriff (PDF)

Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8 + T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma

Clinical cancer research, 2019-11, Vol.25 (21), p.6406-6416

2019

Volltextzugriff (PDF)

A phase I/II study of GSK3145095 alone and in combination with anticancer agents including pembrolizumab in adults with selected solid tumors

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.TPS4165-TPS4165

2019

Volltextzugriff (PDF)

Synergy of TLR4 agonist GSK1795091, an innate immune activator, with agonistic antibody against co-stimulatory immune checkpoint molecule OX40 in cancer immunotherapy

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.12055-12055

2018

Volltextzugriff (PDF)

The HP1 chromo shadow domain binds a consensus peptide pentamer

Current biology, 2000-01, Vol.10 (1), p.27-30

2000

Volltextzugriff (PDF)

Abstract 5554: Preclinical characterization of GSK532, a novel STING agonist with potent anti-tumor activity

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.5554-5554

2018

Volltextzugriff (PDF)

Abstract 6268: Discovery and characterization of the CD96 antibody GSK6097608, a high-affinity, antagonistic anti-CD96 antibody for cancer immunotherapy

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.6268-6268

2022

Volltextzugriff (PDF)

Author Correction: Design of amidobenzimidazole STING receptor agonists with systemic activity

Nature (London), 2019-06, Vol.570 (7761), p.E53-E53

2019

Volltextzugriff (PDF)

Abstract A054: In vivo characterization of Ipilimumab T cell modulation and antitumor activity in a tumor bearing humanized NSG mouse model

Cancer immunology research, 2016-01, Vol.4 (1_Supplement), p.A054-A054

2016

Volltextzugriff (PDF)

1 – 25 von 118

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(60)
Mit Volltextzugriff
(108)

Publikationsform

Sprache

Englisch
(118)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments

Emergence of the CD226 Axis in Cancer Immunotherapy

Distinct HP1 and Su(var)3-9 complexes bind to sets of developmentally coexpressed genes depending on chromosomal location

662 Dissecting the CD226 immune axis in the tumor microenvironment using CyTOF-based high-dimensional immunophenotyping

Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinations

Big opportunities for small molecules in immuno-oncology

The Hinge and Chromo Shadow Domain Impart Distinct Targeting of HP1-Like Proteins

Affinity Selection from Biological Libraries

The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4

Design of amidobenzimidazole STING receptor agonists with systemic activity

Parental Expression of the Chromodomain Protein Pdd1p Is Required for Completion of Programmed DNA Elimination and Nuclear Differentiation

Pdd1p, A Novel Chromodomain-Containing Protein, Links Heterochromatin Assembly and DNA Elimination in Tetrahymena

Immunological profiling of tumor-infiltrating CD8+ T lymphocytes in non-small cell lung cancer, head and neck squamous cell carcinoma, breast cancer, and renal cell cancer

Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo

Response to anti-PD-1 and anti-LAG-3 immune checkpoint blockade is associated with induction of pro-inflammatory Tregs

Multimodal single-cell analysis of human TILs across multiple tumor types reveals heterogeneity and potential opportunities for personalized immunotherapy

Molecular evidence that the myxozoan protists are metazoans

Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8 + T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma

A phase I/II study of GSK3145095 alone and in combination with anticancer agents including pembrolizumab in adults with selected solid tumors

Synergy of TLR4 agonist GSK1795091, an innate immune activator, with agonistic antibody against co-stimulatory immune checkpoint molecule OX40 in cancer immunotherapy

The HP1 chromo shadow domain binds a consensus peptide pentamer

Abstract 5554: Preclinical characterization of GSK532, a novel STING agonist with potent anti-tumor activity

Abstract 6268: Discovery and characterization of the CD96 antibody GSK6097608, a high-affinity, antagonistic anti-CD96 antibody for cancer immunotherapy

Author Correction: Design of amidobenzimidazole STING receptor agonists with systemic activity

Abstract A054: In vivo characterization of Ipilimumab T cell modulation and antitumor activity in a tumor bearing humanized NSG mouse model

Suchergebnisse filtern